Pertussis in infants is often severe, resulting in prolonged hospitalization. Treatment is limited to supportive care. Antibiotics do not significantly alter the course of the disease unless administered during the catarrhal phase. Therapies directed at pertussis toxin, a major virulence factor of Bordetella pertussis, may be beneficial. This study uses the aerosol challenge model to further examine the protective effects of P-IGIV, a new intravenous immunoglobulin product, which has high levels of pertussis toxin antibodies. P-IGIV was prepared as a 4% immunoglobulin G (IgG) solution from the pooled donor plasma from donors immunized with inactivated pertussis toxoid. The IgG pertussis toxin antibody concentration in P-IGIV is >7-fold higher than conventional intravenous immunoglobulin products. In the aerosol challenge model, P-IGIV-treated mice exhibited a dose-dependent decrease in mortality when monitored for 28 days postchallenge. P-IGIV in doses of 2,800, 1,400, and 350 mg/kg significantly reduced mortality compared to saline (P < 0.01)- and human IgIV (P < 0.01)-treated controls. The 50% protective dose of pertussis toxin antibodies in P-IGIV was 147 μg/mL. Recovery of weight gain and normalization of leukocyte counts occurred in all P-IGIV-treated groups but did not exhibit dose-dependent characteristics. Even after 7 days of infection, P-IGIV reversed the effects of pertussis in mice. This study provides further evidence that pertussis toxin antibodies not only play a role in passive protection but can also reverse symptoms of established disease in mice. We feel that P-IGIV deserves further evaluation in children hospitalized with severe pertussis.

Pertussis continues to cause significant morbidity and mortality in young infants and children throughout the world, even in well-immunized populations (13–17, 32). The disease is characterized by severe paroxysmal coughing and choking in infants and whooping in older patients. Pertussis can be severe and even fatal in unimmunized children. Although erythromycin is effective in eliminating Bordetella pertussis from the nasopharynx of infected patients, it does not substantially alter the course of the illness unless it is initiated during the catarrhal phase (7, 41). Additional therapies that decrease the duration and severity of pertussis are needed.

Pittman hypothesized that the systemic manifestations of pertussis are mediated by pertussis toxin (PT); however, the mechanism by which PT might cause paroxysmal coughing has not been elucidated (42). Recent clinical vaccine trials have demonstrated that acellular pertussis vaccines confer protection against pertussis (1, 2, 9, 19, 24, 27, 40, 60, 62). Although many of these vaccines contain secondary antigens, there is evidence that antibodies to PT alone are effective in protecting against severe pertussis, as shown in single-component pertussis toxoid vaccine trials (1, 62). Despite demonstrated efficacy of the vaccines, laboratory measurement of antibodies has not demonstrated a level that corresponds to protection (35, 61). There is still no known therapy for established disease in humans and no therapy directed specifically at PT.

In the past pertussis immunoglobulin preparations made from pooled convalescent sera were investigated in trials that resulted in inconclusive efficacy data (5, 10, 29, 33, 34, 38, 58). In a recent Swedish study, a high-titer pertussis immunoglobulin significantly decreased whooping in hospitalized patients with pertussis (23). Because of the need for further investigation into the use of anti-PT antibodies as therapy for established pertussis, the Massachusetts Public Health Biologic Laboratories (MPHBL) developed a high-titer antipertussis immunoglobulin (P-IGIV) for intravenous administration in humans.

In this study we evaluated the therapeutic effect of P-IGIV on established pertussis by utilizing the aerosol challenge model as first described by Sato et al. (56, 57). We studied the pharmacokinetics of P-IGIV and, specifically, of human anti-PT immunoglobulin G (IgG) antibodies in murine systems. We have also studied the therapeutic potential of P-IGIV by measuring the effect of P-IGIV on leukocytosis, weight gain, and mortality in young mice with established pertussis. We have examined the effect of dose and timing of P-IGIV on established disease. We provide further evidence that pertussis toxin antibodies play a significant role in the treatment of and recovery from established disease.

**MATERIALS AND METHODS**

**Mice.** Female specific-pathogen-free BALB/c mice with natural litters were ordered from Charles River Laboratories and timed to arrive 4 days after dropping their litters. Mice were housed one litter per cage prior to weaning, and five mice per cage after weaning. In autoclaved Low Profile Micro-Isolator (Lab Products, Inc., Maywood, N.J.) filtered top cages with standard bedding. Mice had free access to autoclaved food and water. The cages of mice were placed in a portable HEPA-filtered Ventilated Animal Rack in the BL-2 containment suite. All procedures and handling of mice took place in a BiochemGARD hood. All mice were marked by using standard ear-clipping methods. Blood samples were obtained by retro-orbital bleeding (50 to 100 μl) of appropriately anesthetized animals as described previously (8).

**Bacteria.** Bordetella pertussis 18323 (ATCC 9797; American Type Culture Collection, Rockville, Md.) was recovered from a phylolized stock from the MPHBL and inoculated onto Bordet-Gengou (BG) agar (Difco Laboratories, Detroit, Mich.) with 15% defibrinated horse blood. Growth from 72-h cultures was transferred to fresh BG plates containing 15% defibrinated horse blood and grown at 35°C for 21 h. Bacteria were then removed from the plate by using a sterile loop and resuspended in phosphate-buffered saline (pH 7.4) for use in aerosolization.

The concentration of bacteria in the nebulized solution was set to deliver approximately 10⁶ organisms per ml for 30 min, an optimal concentration as...
demonstrated by other investigators (39, 54). Final concentrations were determined by spectrophotometry and confirmed by subsequent culturing of serial dilutions on BG agar. In one of the timing experiments the nebulized concentration was approximately 10^9 CFU/ml, resulting in slightly higher mortality, but the results were consistent with other experiments, and so the results were combined and analyzed.

**Globulin preparations.** P-IGIV was prepared as a 4% IgG solution by cold ethanol fractionation from the pooled plasma of donors who had been immunized with 50 μg of tetanus toxoid (TNTM)-inactivated pertussis toxoid (PTx). P-IGIV was lyophilized in vials, stored at 4°C, and reconstituted with sterile water to achieve the desired concentration of 10% globulin. Serial dilutions of the 10% solution were used to achieve lower concentrations of P-IGIV. The 10% solution was enriched 40-fold for anti-PT antibodies relative to conventional 5% IGIV and previously licensed intramuscular pertussis immunoglobulin products (20-22, 44) as seen in Table 1.

Mouse polyclonal hyperimmune serum (PHIS) was a control mouse serum made from pooled polyclonal sera of mice immunized with TNTM-inactivated PTx vaccine. Human standard gammaglobulin (HSG) for intramuscular use (MPHBL lot ISG-98) was obtained from the Massachusetts Public Health Biologic Laboratories and was used as a control human gamma globulin in the pharmacology experiments, and Cutter Gamimmune N 5% globulin was used as a control for the aerosol challenge experiments. A comparison of the globulin and anti-PT IgG concentrations of the globulin preparations can be found in Table 3.

**Serologic methods.** (i) Human anti-PT IgG assays. Mouse sera were assayed for detection of human anti-PT antibody concentrations by methods modified from those previously described by Siber et al. (59). Briefly, 96-well plates (Dynatech Immulon 2; Dynatech, Alexandria, Va.) were coated with purified PT (1.0 μg/ml) obtained from the MPHBL. Sensitized plates were incubated overnight at 4°C with serial twofold dilutions of a known A70 human antibody standard or serial fourfold dilutions of the unknown test sera (five dilutions). Bound antibodies were detected by using goat anti-mouse IgG human-absorbed alkaline phosphatase-conjugated antibodies (Caltag Laboratories, San Francisco, Calif.). The anti-PT IgG antibody concentrations for the A70 standard were determined by the Zollinger method as previously described (59, 63). By using the Center for Biologics Evaluation and Review (CBER) pertussis reference antisem (lot 3), 1 μg/ml was determined to be equivalent to 10 CBER U/ml for PT IgG.

(ii) Mouse anti-PT IgG assays. Similar methods were used to detect mouse anti-PT IgG antibodies. Briefly, 96-well plates (Dynatech Immulon 2) were coated with purified PT (1.0 μg/ml) obtained from the MPHBL. Sensitized plates were incubated overnight at 4°C with serial twofold dilutions of PHS obtained from the MPHBL (10 dilutions), or serial fourfold dilutions of the unknown test sera (five dilutions). Bound antibodies were detected by using goat anti-mouse IgG human-absorbed alkaline phosphatase-conjugated antibodies (Caltag Laboratories, San Francisco, Calif.). The anti-PT IgG antibody concentrations for the A70 standard were determined by the Zollinger method as previously described (59, 63).

**Pharmacokinetic analysis.** The pharmacokinetics of P-IGIV were studied by a comparison of class- and antigen-specific antibodies. The mean volume of distribution (V) and the half-life (t1/2) of anti-PT antibodies were calculated to compare the pharmacokinetics of PT-specific antibodies after intravenously (i.v.) and intramuscularly administered P-IGIV in mice. The half-life calculations were determined in intramuscularly administered mice, t1/2 was calculated, while t1/2 was calculated by using the terminal elimination phase (3 to 90 days). The volume of distribution and half-life calculations are reported as geometric means. The 50% probative dose (P50) for P-IGIV was estimated by the Reed and Muench method as previously described (46).
control human immunoglobulin (HuISG) given in a dose of 2,800 mg/kg in 0.2 ml i.p. The geometric mean peak concentration of anti-PT IgG antibody of 2.14 µg/ml observed 6 h after HuISG administration was significantly lower than that with i.p.-administered P-IGIV ($P = 0.024$). The geometric mean $V$ of HuISG based on levels at 3 days was 2.33 ml, and the $t_{1/2}$ was 6.9 days.

In order to compare the clearance of human and murine IgG in the model, we measured murine anti-PT IgG antibodies after i.p. administration of PHIS in a 0.2-ml volume. The peak geometric mean level of anti-PT IgG antibodies of 101.8 µg/ml was reached in 3 h. The geometric mean $V$ based on levels at 3 days was 2.00 ml, and the $t_{1/2}$ was 5.8 days.

**Dose response of P-IGIV.** Saline-treated controls showed 50% mortality by day 11 and 100% mortality by day 14. The Gamimmune-treated control mice showed 50% mortality by day 13 and 100% mortality by day 17. The P-IGIV-treated mice exhibited a dose-dependent decrease in mortality, monitored for 28 days postchallenge (Tables 3 and 4). P-IGIV in doses of 2,800, 1,400, and 350 mg/kg all significantly reduced mortality compared to saline ($P < 0.01$)- and Gamimmune ($P < 0.01$)-treated controls. P-IGIV in a dose of 700 mg/kg also reduced mortality compared to saline and Gamimmune but because of one outlier did not achieve statistical significance ($P > 0.05$). Even after established infection for 7 days, P-IGIV reversed the mortality due to pertussis in mice in the aerosol challenge model, exhibiting dose-dependent characteristics (Table 4). Using the Reed and Muench estimation method, the $PD_{50}$ for P-IGIV was found to be approximately 0.8% globulin, which corresponds to approximately 147 µg of anti-PT IgG antibodies per ml.

By 14 days after challenge all mice treated with saline and Gamimmune showed a marked leukocytosis and weight loss prior to death. Recovery of weight gain and normalization of WBC counts occurred in all P-IGIV-treated groups but did not exhibit dose-dependent characteristics (Table 5). Mean WBC counts at day 7 postchallenge (pretreatment) were not statistically different. Although there was a significant rise in the WBC count prior to treatment, all P-IGIV-treated groups showed normalization of leukocytosis by 28 days postchallenge; that is, the WBC counts were no longer statistically different from those of uninfected controls ($P > 0.05$). Mean weights were statistically similar for all groups on the day of challenge. All P-IGIV-treated groups were smaller than uninfected controls on day 14 postchallenge ($P < 0.01$) but had recovered their weight by day 28 and were no longer statistically different ($P > 0.05$). In fact, the survivors in all P-IGIV-treated groups exhibited accelerated weight gain in order to reach the normal weight curve of the uninfected controls (Table 5). The saline-treated controls all lost a significant amount of weight compared to the uninfected controls ($P < 0.01$) prior to their death. Even after established infection for 5 to 7 days, P-IGIV reversed the severe effects of pertussis such as leuko-

---

**TABLE 2. Pharmacokinetics of mouse and human anti-PT IgG antibodies in BALB/c mice**

| Preparation | Anti-PT IgG dose (mg/kg) | Observed peak (h) | Peak levela (µg/ml) | $V$ (ml) | $t_{1/2}$ (days) |
|-------------|-------------------------|------------------|---------------------|---------|-----------------|
| P-IGIV (i.v.) | 146.6                   | 1                | 89.3               | 4.26    | 7.8             |
| P-IGIV (i.p.) | 146.6                   | 3                | 38.1               | 3.53    | 7.0             |
| PHIS (i.p.) | 181.9                   | 3                | 101.8              | 2.00    | 5.8             |
| HuISG (i.p.) | 4.4                     | 6                | 2.14               | 2.33    | 6.9             |

$a$ All values reported are geometric means.

$b$ The peak P-IGIV administered i.p. was significantly higher than the peak HuISG ($P < 0.05$).
cytosis and weight loss in mice in the aerosol challenge model but, unlike mortality, these effects did not exhibit dose-dependent characteristics.

**Effects of timing.** Saline-treated controls showed 50% mortality by day 12 and 100% mortality by day 13. Mice treated with P-IGIV on day 6 or 7 post-aerosol challenge had greater than 50% survival at day 28 (Table 6). Although there appeared to be a trend toward reducing mortality with earlier treatment, only when P-IGIV was administered on day 6 or 7 postinfection did it achieve a statistically significant improvement over saline ($P < 0.01$) (Table 6).

By 6 days after challenge all mice treated with saline showed a marked leukocytosis and weight loss prior to death. Recovery of weight gain and normalization of WBC counts occurred in all P-IGIV-treated groups but did not exhibit dose-dependent characteristics (Table 7). Mean WBC counts at day 3 postchallenge (pretreatment) were not statistically different for any of the groups infected with *B. pertussis*. Although there was a significant rise in WBC count prior to treatment ($P < 0.05$), all P-IGIV-treated groups showed normalization of leukocytosis by 28 days postchallenge and were no longer statistically different from uninfected controls ($P > 0.05$). Mean weights were statistically similar for all groups on the day of challenge. All P-IGIV-treated animals were significantly smaller than uninfected controls on day 14 postchallenge ($P < 0.01$) but had recovered their weight by day 28 ($P > 0.05$ versus uninfected controls). The saline-treated controls all lost a significant amount of weight prior to their deaths.

**DISCUSSION**

There is compelling evidence to date that PT antibodies alone provide passive protection against pertussis. Although protective levels of PT antibodies have not been determined, vaccine trials and specifically those using single component acellular PT vaccines have shown that antibodies against PT alone can protect against pertussis. The addition of other antigens such as filamentous hemagglutinin (FHA), agglutinins, and 69-kDa protein only add minimal protection to that achieved by PTx alone (1, 9, 62). It is known that patients convalescing from pertussis mount a high antibody response to PT, which approximates the onset of gradual recovery from the disease (40, 41).

It is believed that PT may be responsible for the characteristic cough of pertussis whether locally or centrally mediated. The therapeutic role of anti-PT antibodies in patients with established pertussis was not conclusively demonstrated in the past. Pertussis immunoglobulin preparations made from pooled convalescent sera were investigated in trials that resulted in inconclusive efficacy data (5, 10, 29, 33, 34, 38, 58). Subsequent testing has shown that some of these products had low levels of anti-PT IgG antibodies, as seen in Table 1. By using a pertussis immunoglobulin made at Institute Merieux, Granström et al. demonstrated that PT antibodies significantly reduced whooping in children (23). P-IGIV was developed as an i.v. product to further evaluate the role of PT antibodies in the treatment of pertussis. Two important differences in P-IGIV should be mentioned. The Swedish product was given intramuscularly, which results in lower peak levels of PT antibodies as measured by enzyme-linked immunosorbent assay (ELISA) and CHO cell assay. Because P-IGIV has a high titer of anti-PT antibody it has promise as a therapeutic agent, especially when given i.v.

There are several animal models in which antibodies to PT have been shown to be protective, such as histamine challenge, intracerebral inoculation, and intranasal challenge (18, 26, 28, 43, 47). We chose the aerosol challenge model as described by Sato et al. (56) to further study P-IGIV since it has many

---

**TABLE 5. Effects of P-IGIV on leukocytosis and weight loss after aerosol challenge in mice**

| Group (dose [mg/kg]) | Geometric mean WBC counts (10$^3$ cells/mm$^3$) at (days postchallenge): | Change in wt (g) at (days postchallenge): |
|---------------------|-------------------------------------------------|------------------------------------------|
|                     | 3 days$^a$ | 7 days$^b$ | 14 days | 21 days | 28 days | 0–7 days$^c$ | 7–14 days | 0–14 days | 0–28 days$^d$ |
| P-IGIV              |           |           |         |         |         |         |           |           |           |           |
| 2,800               | 30.3      | 70.2      | 34.7    | 29.6    | 5.1     | –0.3    | 2.2       | 1.9       | 9.5       |
| 1,400               | 38.5      | 76.0      | 15.7    | 32.7    | 7.4     | –0.3    | 2.9       | 2.6       | 9.0       |
| 700                 | 32.1      | 92.8      | 25.7    | 14.2    | 8.5     | –0.6    | 1.8       | 1.2       | 9.6       |
| 350                 | 26.1      | 54.4      | 12.9    | 6.0     | 6.0     | 0.7     | 3.4       | 4.1       | 10.3      |
| 175                 | 23.7      | 71.0      | 75.8    | 8.3     | 5.8     | –0.1    | 2.9       | 2.9       | 9.9       |
| 88                  | 20.0      | 85.3      | 83.5    | 12.5    | 6.0     | 0.5     | 2.4       | 2.9       | 10.0      |
| Gamimmune           | 28.0      | 130.2     | 194.7   |         |         | 0.4     | —         |           |           |
| Saline              | 48.9      | 175.7     | —$^f$   |         |         | –0.5    | —         |           |           |
| Uninfected controls | 7.7       | 6.0       | 9.3     | 8.7     | 7.1     | 3.7     | 3.6       | 7.3       | 9.2       |

$^a$ There was no difference between all P-IGIV groups and the saline group ($P > 0.05$), except for the 88-mg/kg P-IGIV group ($P < 0.05$).  
$^b$ All P-IGIV values were significantly higher than the uninfected controls ($P < 0.01$), except for the 175-mg/kg P-IGIV group ($P > 0.05$).  
$^c$ All P-IGIV groups had WBC counts similar to those of uninfected controls ($P > 0.05$).  
$^d$ By day 14 all P-IGIV groups weighed significantly less than the uninfected controls ($P < 0.01$).  
$^e$ By day 28 all P-IGIV groups had regained normal weight ($P > 0.05$).  
$^f$ —, all mice were dead prior to day 14.
similarities to pertussis infection in infants. Although mice do not whoop or cough, the infection is established by adherence of the organisms to the columnar respiratory epithelium of mice, followed by proliferation of organisms in the lungs, lymphocytosis, weight loss, and death (56). There is evidence that illness in mice is produced by the elaboration of PT, which has been shown to cause lymphocytosis and weight loss (25). As in humans, infant mice manifest more severe illness than adult mice do (56).

Both passive and active PT antibodies have been shown to provide protection in mice when given prior to aerosol challenge with *B. pertussis* (51, 52, 54, 55, 57). Although monoclonal and polyclonal antibodies to PT provide protection when given prior to aerosol challenge (39, 51, 52, 54, 55, 57), the therapeutic benefits after established aerosol infection have not been thoroughly examined. Sato and Sato have shown that monoclonal and polyclonal antibodies to PT can reverse the severe manifestations of pertussis in mice even when administered 3 to 9 days after aerosol challenge (54).

In this study we have shown by using the aerosol challenge model that we can reverse the severe effects of established infection with *B. pertussis* in mice. Mortality demonstrated dose-dependent characteristics. The PD<sub>50</sub> was approximately 250 µg of P-IGIV (0.8% globulin) per ml. Unlike mortality, the reduction of leukocytosis and the resumption of weight gain did not exhibit dose-dependent characteristics. This would suggest that lymphocytosis and weight loss are unrelated to the amount of elaborated PT or that the amount of PT antibodies was not dilute enough to exhibit dose-dependent characteristics. This would also suggest that the mechanisms for mortality might not be related to leukocytosis or to weight loss.

It has long been believed that once PT is elaborated it becomes irreversibly bound to target tissues and therefore, once established, the disease would be unresponsive to therapy. Adler and Morse have shown that PT-induced lymphocytosis is reversible with anti-PT antibodies (3). In studies with the aerosol challenge model, a few investigators have suggested that PT antibodies could also reverse other manifestations of illness in mice, such as mortality and weight loss, even when given 3 days after established infection. We have demonstrated that P-IGIV given early was clearly more effective than a later administration; however, even when it was given 8 days after established infection, mice showed resolution of leukocytosis and reestablished weight gain.

Although it is widely accepted that immunity to pertussis is primarily dependent on a humoral response, there has been recent work suggesting that cell-mediated immunity plays an important role in protection against pertussis both in humans and in animals (4, 11, 12, 30, 31, 36, 45, 48). This cell-mediated response has also been shown to be important in conferring immunity after active immunization with both whole-cell vaccines and acellular pertussis vaccines (36, 45, 49, 50). This cell-mediated immunity in mice infected with *B. pertussis* is characterized by the induction of a T-cell-mediated response. There is some evidence that pertussis infection and whole-cell vaccines both induce a CD4<sup>+</sup> Th1 response, whereas acellular pertussis vaccines induce a response more characteristic of CD4<sup>+</sup> Th2 (6, 45, 49, 50).

In a recent study by Mills et al. (37), it was demonstrated that cell-mediated immunity and PT-IgG antibody response play complementary roles in conferring immunity in the aerosol challenge model. They compared three whole-cell and five acellular pertussis vaccines and demonstrated a high correlation between clinical vaccine efficacy in children and *B. pertussis* clearance from the lungs of immunized mice with the aerosol challenge model. Despite this correlation, the precise mechanisms for immunity need to be further investigated. In this study we have provided further evidence for the important role of anti-PT IgG antibodies in the immune response but do not exclude the complementary role of cell-mediated immunity.

In this study we have given further evidence that PT antibodies not only play a major role in passive protection but also can reverse symptoms of established disease for at least 7 days in mice in the aerosol challenge model. This finding has implications for the treatment of children who often present 1 to 2 weeks after the onset of symptoms. P-IGIV given in comparable doses to those proposed for human trials was significantly better at reducing mortality, lowering leukocytosis, and restoring normal weight gain than saline and even standard human gamma globulin.

**ACKNOWLEDGMENTS**

This work was supported in part by a grant from the National Institutes of Health.

We are grateful to Claudette Thompson for her assistance as laboratory manager. We are grateful to the Massachusetts Public Health Biologic Laboratories for providing vaccine and toxins.

**REFERENCES**

1. Ad Hoc Group for the Study of Pertussis Vaccines. 1988. Placebo-controlled trial of two acellular pertussis vaccines in Sweden—protective efficacy and adverse events. Lancet 4:955–960.
2. Ad Hoc Group for the Study of Pertussis Vaccines. 1997. A randomized controlled trial of a two-component, a three-component and a five-component acellular pertussis vaccine and a British whole-cell pertussis vaccine. Lancet 350:1569–1577.
3. Adler, A., and S. I. Morse. 1973. Interaction of lymphoid and nonlymphoid cells with the lymphocytosis-promoting factor of *Bordetella pertussis*. Infect. Immun. 7:601–617.

**TABLE 7. Effects of timing of P-IGIV on leukocytosis and weight loss after aerosol challenge in mice**

| Group        | Geometric mean WBC count (10<sup>9</sup> cells/mm<sup>3</sup>) at (days postchallenge) | Change in wt (g) at (days postchallenge)<sup>a</sup> |
|--------------|---------------------------------------------|---------------------------------------------|
|              | 3 days | 6 days | 10 days | 14 days | 0–7 days | 7–14 days | 0–14 days | 0–28 days |
| Uninfected controls | 5.9 | 7.0 | 7.3 | 10.2 | 3.7 | 3.9 | 7.6 | 9.6 |
| P-IGIV<sup>b</sup> | Days 6 and 7 | 28.5 | 104.1 | 70.5 | 45.7 | 0.5 | 2.5 | 3.1 | 8.9 |
|                  | Days 8 and 9 | 29.1 | 157.9 | 219.6 | 68.5 | -0.1 | -0.04 | -0.1 | 3.6 |
|                  | Days 10 and 12 | 23.2 | 111.3 | 259.3 | 237.5 | 1.6 | 1.7 | 0.1 | 1.9 |
|                  | Days 14 and 18 | 24.2 | 108.9 | 263.4 | 288.5 | 1.9 | 1.8 | 0.2 | 0.3 |
| Saline         | 31.5 | 98.3 | 288.5 | |

<sup>a</sup> All survivors in the P-IGIV-treated groups showed normalization of leukocytosis by day 28 postchallenge, a finding not statistically different from the results for uninfected controls at day 28 (P > 0.05).

<sup>b</sup> Change in geometric mean.
Ausiello, C. M., F. Urbani, A. La Sala, R. Lande, and A. Cassone. 1997. Detection of Bordetella pertussis associated with the alveolar macrophages of children with human immunodeficiency virus infection. Infect. Immun. 65:4715–4719.

Aussone, C. M., C. Ausiello, F. Urbani, R. Lande, and S. Giuliano for the Progetto Pertosse-CMI Working Group. 1997. Cell-mediated and antibody responses to Bordetella pertussis antigens in children vaccinated with acellular and whole-cell pertussis vaccines. Arch. Pediatr. Adolesc. Med. 151:283–289.

Bass, J. W. 1991. Safety and immunogenicity of Bordetella pertussis respiratory infection of mice as predictors of clinical performance. Vaccine 9:525–530.

Bialy, W. C. 1990. Vaccine efficacy for a variety of clinical case definitions. Food and Drug Administration publication no. 260. U.S. Government Printing Office, Washington, D.C.

Bradford, W. L. 1935. Use of convalescent blood in whooping cough. With a review of the literature. Am. J. Dis. Child. 50:918–925.

Brookmeyer, R. C., N. Tannis, and P. Steiner. 1984. Techniques of experimentation, p. 289–303. In J. G. Fox, B. J. Cohen, and F. M. Loew (ed.), Laboratory animal medicine. Academic Press, Inc., New York, N.Y.

Blackwelder, W. C. 1990. Vaccine efficacy for a variety of clinical case definitions. Food and Drug Administration publication no. 260. U.S. Government Printing Office, Washington, D.C.

Bordetella pertussis and pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis. Infect. Immun. 66:594–602.

Bouma, N. J., T. A. drill, and J. E. S. J. 1997. The pro- tective role of the filamentous hemagglutinin and the lymphocyte-promoting factor of Bordetella pertussis in mice. J. Infect. Dis. 158:623–633.

Olin, P., and J. Storsaeter. 1989. The efficacy of acellular pertussis vaccines. JAMA 261:560.

Olson, L. C. 1975. Pertussis. Medicine 54:427–469.

Pittman, M. 1984. The concept of pertussis as a toxic-mediated disease. Pediatr. Infect. Dis. J. 3:467–468.

Pittman, M., B. L. Furman, and A. C. Wardlaw. 1980. Bordetella pertussis respiratory tract infection in the mouse: pathophysiological responses. J. Infect. Dis. 142:56–66.

Pittman, M., R. A. Gardner, and J. F. Marshall. 1979. Evaluation of the protective activity of anti-pertussis serum in mice. J. Infect. Dis. 142:251–259.

Redhead, K. A., A. J. Chiba, Y. Sato, and K. H. G. Mills. 1993. Effective immunization against Bordetella pertussis respiratory infection in mice is dependent on the induction of cell-mediated immunity. Infect. Immun. 61:3198.

Reed, L. J., and H. Muench. 1938. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27:493–497.

Robinson, A., A. Gorringle, and M. Fernandez. 1989. Serospecific protection of mice against intranasal infection with Bordetella pertussis. Vaccine 7:321–324.

Ryan, M. G., Murphy, L. Gothers, L. Nilsson, J. Storsaeter, and K. H. G. Mills. 1997. Bordetella pertussis respiratory infection in children is associated with preferential activation of type 1 Th cells. J. Infect. Dis. 175:1246–1250.

Ryder, L., L. Gothers, J. Storsaeter, and K. H. G. Mills. 1997. R. pertussis-specific Th1/Th2 cells generated following respiratory infection or immunization with an acellular vaccine: comparison of the T cell cytokine profiles in infants and mice. Dev. Biol. Stand. 89:251–259.

Scheiblum, I. E., and J. G. Bullowa. 1991. Safety and immunogenicity of Bordetella pertussis respiratory infection of mice with targeted disruptions in IFN-receptor or immunoglobulin M chain genes. J. Exp. Med. 186:1843–1851.

Sato, H., A. Ito, J. Chiba, and Y. Sato. 1984. Monoclonal antibody against pertussis toxin: effect on toxin activity and pertussis infections. Infect. Immun. 46:422–428.

Sato, H., and Y. Sato. 1984. Bordetella pertussis infection in mice: correlation of specific antibodies against two antigens, pertussis toxin, and filamentous hemagglutinin with mouse protectivity in an intracerebral or aerosol challenge system. Infect. Immun. 46:415–421.

Sato, H., and Y. Sato. 1988. Pathogenesis and immunity in pertussis, p. 308–325. In Animal models of pertussis. John Wiley & Sons, Ltd., London, United Kingdom.

Sato, H., and Y. Sato. 1990. Protective activities of the filamentous hemagglutinin and to filamentous hemagglutinin in immunity to pertussis. Infect. Immun. 58:3369–3374.

Sato, Y., K. Izumiya, H. Sato, J. L. Cowell, and C. R. Manclark. 1980. Role of antibody to leukocytosis promoting factor, hemagglutinin and to filamentous hemagglutinin in immunity to pertussis. Infect. Immun. 31:1223–1231.

Sato, Y., K. Izumiya, H. Sato, J. L. Cowell, and C. R. Manclark. 1980. Aerolization of mice with Bordetella pertussis. Infect. Immun. 29:261–266.

Sato, Y., I. Kazumi, H. Sato, J. L. Cowell, and C. R. Manclark. 1985. Role of antibody to filamentous hemagglutinin and to leukocytosis promoting factor-hemagglutinin in immunity to pertussis. Semin. Infect. Dis. 4:308–303.

Scheiblum, I. E., and J. G. Bullowa. 1991. Specific immunoglobulin for treatment of whooping cough. Lancet 338:1230–1233.

Greco, D., S. Salsmono, P. Mastrantonio, M. Guilio, A. G. Tozzi, A. Amorena, M. L. Giori Dell’Ait, A. Giannanco, P. Panel, W. C. Blackwelder, D. L. Klein, S. S. F. Wassilak, and the Progetto Pertosse-CMI Working Group. 1996. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N. Engl. J. Med. 334:341–348.

Gupta, R. K., S. N. Saxena, B. S. Sunith, and S. Abhajna. 1988. Effects of purified pertussis components and lipopolysaccharide on the results of the mouse weight gain test. J. Biol. Stand. 16:321–331.

Gupta, R. K., S. N. Saxena, and B. S. Sharma. 1990. Protection of mice inoculated with purified pertussis toxins and filamentous haemagglutinin against intracerebral challenge with Bordetella pertussis. Vaccine 8:269.

Gustafsson, L., H. O. Hallander, P. Olin, E. Reizenstein, and J. Storsaeter. 1996. A controlled trial of a two-component acellular, a five component acellular, and a whole-cell pertussis vaccine. N. Engl. J. Med. 334:349–355.

Halperin, S. A., A. A. Heifetz, and A. Kassina. 1988. Experimental respiratory infection with Bordetella pertussis in mice: comparison of two methods. Clin. Invest. Med. 11:297–301.

Hink, J. H., Jr., and F. F. Johnson. 1950. The occurrence in human plasma of antibodies to the H pertussis. J. Immunol. 64:39–43.

Mahon, B. P., M. Ryan, F. Griffin, and K. H. G. Mills. 1996. interleukin-12 is produced by macrophages in response to live or killed Bordetella pertussis and is a prerequisite for the priming of an acute immunity of mice by promoting induction of TH cells. Infect. Immun. 64:5295–5301.

Mahon, B. P., F. Griffin, B. Sheahan, and K. H. G. Mills. 1997. Atypical disease following Bordetella pertussis respiratory infection of mice with targeted disruptions in IFN-receptor or immunoglobulin M chain genes. J. Exp. Med. 186:1843–1851.
of hydrogen peroxide-inactivated pertussis toxoid in 18-month-old children. Vaccine 9:735–740.

60. Simondon, F., M. P. Preziosi, A. Yam, C. T. Kane, L. Chabirand, I. Itelman, G. Sanden, S. Mboyp, A. Hoffenbach, K. Knudsen, N. Guiso, S. Wassilak, and M. Cadoz. 1997. A randomized double blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine 15:1606–1612.

61. Standfast, A. F. B. 1958. The comparison between field trials and mouse protection tests against intranasal and intracerebral challenges with Bordetella pertussis. Immunology. 2:135.

62. Trollofors, B., J. Taranger, T. Lagergard, L. Lind, V. Sundh, G. Zackrisson, C. U. Lowe, W. Blackwelder, and J. B. Robbins. 1995. A placebo-controlled trial of a pertussis-toxoid vaccine. N. Engl. J. Med. 333:1045–1050.

63. Zollinger, W. D., and J. W. Boslego. 1981. A general approach to standardization of the solid-phase radioimmunoassay for quantitation of class-specific antibodies. J. Immunol. Methods 46:129–140.